> While members of the psychedelic cohort received 25 milligrams of psilocybin during the sessions, considered a medium-to-heavy dose of the drug, those in the antidepressant group received 1 milligram. Such a low dose is typically provided in psychedelic studies in lieu of a placebo Doesn't seem like well-designed study.
Studies like these are inherently difficult, this isn’t an issue of poor design.